ClinicalTrials.gov
Cure8 trial brief
Why This Matters
The study explores engineering HSPCs to induce IL-10–mediated, antigen-specific regulatory responses, which could lead to new cell-based strategies for children with refractory IBD who do not respond to current treatments.
Who Should Pay Attention
Parents and caregivers of pediatric patients with refractory IBD; pediatric gastroenterologists and clinicians; researchers in cell therapy, immune tolerance, and IBD.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment80 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
The investigators will collect intestinal tissue and peripheral blood from pediatric IBD patients and controls to profile inflammatory and regulatory immune cells, measure circulating CD34+ HSPCs, and test ex vivo expansion and engineering protocols.
They plan to evaluate responses to commensal-derived antigens and whether engineered HSPCs can drive antigen-specific Tr1 cells in vitro. The registry lists this as an observational, not-yet-recruiting study with planned enrollment and sample-collection procedures.
Keep In Mind
This is an observational, not-yet-recruiting study registered on ClinicalTrials.gov focusing on preclinical and ex vivo translational work (sample collection, cell characterization, and in vitro assays). It does not provide clinical efficacy or safety results.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorIRCCS San Raffaele
Trial IDNCT07740499
Study typeObservational
Enrollment80 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 31, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance...
Atopic Dermatitis and Risk of Inflammatory Bowel Disease in Children: A Systematic Review and Meta-Analysis
This review found that children with atopic dermatitis have a modestly higher risk of later developing IBD (both Crohn’s disease and ulcerative colitis). Awareness of this association may help clinicians and families...
A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
People with IBD who are breastfeeding and are taking guselkumab may want data on how much of the drug gets into breast milk and the estimated infant exposure. This study aims to provide those measurements for the Q4W and...